Sepsis syndrome

American Surgeon

Volumn 66, Issue 2, 2000, Pages 126-132

  Fry, Donald E ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TRANSLOCATION; BLOOD CLOTTING; COMPLEMENT SYSTEM; CONFERENCE PAPER; CYTOKINE PRODUCTION; HUMAN; INFECTION; INJURY; KALLIKREIN KININ SYSTEM; MAST CELL; MICROCIRCULATION; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE; WOUND;

CHEMOKINES; HUMANS; SOFT TISSUE INFECTIONS; SURGICAL WOUND INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033961638     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Goris RJ, Beokhorst PA, Nuytinck KS. Multiple organ failure: Generalized autodestructive inflammation. Arch Surg 1985; 120:1109-15.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864.
3. Cicala C, Cirino G. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-24.
4. Weksler BB. Roles for human platelets in inflammation. Prog Clin Biol Res 1988;283:611-38.
5. Hargreaves KM, Troulles ES, Dionne RA, et al. Bradykinin is increased during acute and chronic inflammation: Therapeutic implications. Clin Pharmacol Ther 1988;44:613-21.
6. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann Rev Pharmacol Toxicol 1990;30:535-60.
7. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79.
8. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 1990;346:274-6.
9. Mollnes TE, Fosse E. The complement system in trauma-related and ischemic tissue damage: A brief review. Shock 1994; 2:301-10.
10. Luster AD. Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
11. Klebanoff SJ, Vedes MA, Harlan JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986;136:4220-5.
12. Brown EJ, Lindberg FP. Leukocyte adhesion molecules in host defense against infection. Ann Med 1996;28:210-8.
13. Townsend MC, Hampton WW, Haybron DM, et al. Effective organ blood flow and bioenergy status in murine peritonitis. Surgery 1986;100:205-13.
14. Schirmer WJ, Townsend MC, Schirmer JM, et al. Galactose elimination kinetics in sepsis: Correlation of hepatic blood flow with function. Arch Surg 1987;122:349-54.
15. Asher EF, Rowe RL, Garrison RN, Fry DE. Experimental bacteremia and hepatic nutrient blood flow. Circ Shock 1986;20: 43-9.
16. Schirmer WJ, Schirmer JM, Naff GB, Fry DE. Systemic complement activation produces hemodynamic changes characteristic of sepsis. Arch Surg 1988;123:316-21.
17. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr. Multiple system organ failure: The role of uncontrolled infection. Arch Surg 1980;115:136-40.
18. Fry DE, Garrison RN, Williams HC. Patterns of morbidity and mortality in splenectomy for trauma. Am Surg 1980;46:28-32.
19. Deitch EA, Rutan R, Waymack JP. Trauma, shock, and gut translocation. New Horiz 1996;4:289-99.
20. Dyess DL, Garrison RN, Fry DE. Candida sepsis: Implications of polymicrobial blood-borne infection. Arch Surg 1985;120: 345-8.
21. Garrison RN, Fry DE, Berberich S, Polk HC Jr. Enterococcal bacteremia: Clinical implications and determinants of death. Ann Surg 1982;43-47.
22. Meldrum DR, Cleveland JC Jr, Moore EE, et al. Adaptive and maladaptive mechanisms of cellular priming. Ann Surg 1997; 226:587-98.
23. Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Ann Surg 1974;139:69.
24. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1-5.
25. Cohen J, Carlet J. Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor- in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431-40.
26. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirming interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigation Group. Crit Care Med 1997;25:1115-24.
27. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndromes and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): Results of a randomized, double-blind, placebo-controlled trial. CP-1027 SIRS and Sepsis Study Group. JAMA 1997;277:482-487.
28. Altwegg M, Kayser FH. Will cultures survive? The role of molecular test in diagnostic bacteriology. Infection 1997;25: 265-8.
29. Molvig J, Baek L, Christensen P, et al. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumor necrosis factor , and prostaglandin E2 shows stable interindividual differences. Scand J Immunol 1988;27:705-16.
30. Maher DW, Davis I, Boyd AW, Morstyn G. Human interleukin-4: An immunomodulator with potential therapeutic application. Prog Growth Factor Res 1991;3:43-56.
31. De Waal Malefyt R, Abrams J, Bennet B, et al. Interleukin 10 inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 production by monocytes. J Exp Med 1991; 174:1209.
32. De Vries JE. Molecular and biological characteristics of interleukin-13. Chem Immunol 1996;63:204-18.